Connect your AI

Perspective Therapeutics CATX Restricted Cash

Restricted Cash at other companies

CytomX TherapeuticsCTMX

$1.53M+48.5%

ImmunomeIMNM

$210K+110%

Lantheus HoldingsLNTH

$1.71M+1.8%

Tango TherapeuticsTNGX

$0-100%

Septerna, Inc.SEPN

$905K0.0%

Roivant SciencesROIV

——

Other financials

Income statement

Revenue$2.2M+27.3%

Gross profit$738.0K+78.3%

Operating income-$28.3M-29.5%

Net income-$26.2M-44.1%

EPS (diluted)-$0.250.0%

Balance sheet

Cash & equivalents$54.0M+21.5%

Total debt$4.2M+10.9%

Total equity$347.4M+22.1%

Total assets$410.8M+24.7%

Cash flow

Operating cash flow-$31.5M-45.8%

CapEx$6.9M+47.3%

Free cash flow-$38.3M-46.1%

Valuation

Market cap$342.14M+33.2%

Enterprise value$292.34M+35.2%

P/S34.2×+19.6×

Profitability

Gross margin33.1%-7.1pp

Operating margin-292.7%-553pp

Net margin-218.4%-781pp

FCF margin-1,073.3%—

Returns & leverage

Return on equity-35.2%+2.3pp

Debt / equity0×0.0×

Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsNoncurrent.

The official record: Perspective Therapeutics’s 10-Q, filed August 13, 2025, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Perspective Therapeutics's restricted cash?: Perspective Therapeutics (CATX) reported restricted cash of $0 in Q2 2025.
How has Perspective Therapeutics's restricted cash changed year-over-year?: Perspective Therapeutics's restricted cash decreased by 100.0% year-over-year, from $182K to $0.
What is the long-term trend for Perspective Therapeutics's restricted cash?: Over 4 years (2020 to 2024), Perspective Therapeutics's restricted cash has grown at a -100.0% compound annual growth rate (CAGR), from $182K to $0.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.